SG 221
Alternative Names: SG-221Latest Information Update: 17 Oct 2023
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 12 Oct 2023 Discontinued - Preclinical for Multiple myeloma in USA (IV) prior to October 2023 (Sana Biotechnology pipeline, October 2023)
- 23 Apr 2021 SG 221 is available for licensing as of 23 Apr 2021. https://ir.sana.com/static-files/93b5ef45-6308-4592-9bb6-0adb66d879db 3556868
- 16 Apr 2021 Sana Biotechnology plans to file an IND application with the US FDA for Multiple myeloma in the year 2023